An open-label comparison of nabilone and gabapentin as adjuvant therapy or monotherapy in the management of neuropathic pain in patients with peripheral neuropathy

Pain Practice

Volumn 11, Issue 4, 2011, Pages 353-368

  Bestard, Jennifer A ^a   Toth, Cory C ^a  

^a UNIVERSITY OF CALGARY   (Canada)

Author keywords

Cannabinoid; Gabapentin; Nabilone; Neuropathic pain; Peripheral neuropathy

Indexed keywords

GABAPENTIN; NABILONE;

ADD ON THERAPY; ADJUVANT THERAPY; ADULT; ANXIETY; ARTICLE; BRIEF PAIN INVENTORY; CONTROLLED STUDY; DEPRESSION; DIZZINESS; DRUG EFFICACY; DRUG WITHDRAWAL; FATIGUE; FEMALE; HOSPITAL ANXIETY AND DEPRESSION SCALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NEUROPATHIC PAIN; OPEN STUDY; OUTCOME ASSESSMENT; PERIPHERAL NEUROPATHY; QUALITY OF LIFE; QUESTIONNAIRE; RATING SCALE; SEDATION; SHORT FORM 36; SIDE EFFECT; SLEEP; TREATMENT OUTCOME; VISUAL ANALOG SCALE;

EID: 79960192047     PISSN: 15307085     EISSN: 15332500     Source Type: Journal    
DOI: 10.1111/j.1533-2500.2010.00427.x     Document Type: Article

References (44)

1. Backonja MM, Galer BS. Pain assessment and evaluation of patients who have neuropathic pain. Neurol Clin. 1998;16:775-790.
2. Hughes RA. Peripheral neuropathy. BMJ. 2002;324:466-469.
3. Gordon A, Choiniere M, Collet JP. The humanistic burden of neuropathic pain in Canada. J Outcomes Res. 2006;2006:23-35.
4. Mauskopf J, Austin R, Dix L, Berzon R. The Nottingham Health Profile as a measure of quality of life in zoster patients: convergent and discriminant validity. Qual Life Res. 1994;3:431-435.
5. McDermott AM, Toelle TR, Rowbotham DJ, etal. The burden of neuropathic pain: results from a cross-sectional survey. Eur J Pain. 2006;10:127-135.
6. Meyer-Rosberg K, Kvarnstrom A, Kinnman E, etal. Peripheral neuropathic pain-a multidimensional burden for patients. Eur J Pain. 2001;5:379-389.
7. Gilron I, Bailey JM, Tu D, etal. Morphine, gabapentin, or their combination for neuropathic pain. N Engl J Med. 2005;352:1324-1334.
8. Moulin DE, Clark AJ, Gilron I, etal. Pharmacological management of chronic neuropathic pain-consensus statement and guidelines from the Canadian Pain Society. Pain Res Manag. 2007;12:13-21.
9. Di Marzo V, Petrocellis LD. Plant, synthetic, and endogenous cannabinoids in medicine. Annu Rev Med. 2006;57:553-574.
10. Hohmann AG, Suplita RL 2nd. Endocannabinoid mechanisms of pain modulation. AAPS J. 2006;8:E693-E708.
11. Beltramo M, Bernardini N, Bertorelli R, etal. CB2 receptor-mediated antihyperalgesia: possible direct involvement of neural mechanisms. Eur J Neurosci. 2006;23:1530-1538.
12. Bridges D, Ahmad K, Rice AS. The synthetic cannabinoid WIN55, 212-2 attenuates hyperalgesia and allodynia in a rat model of neuropathic pain. Br J Pharmacol. 2001;133:586-594.
13. Fox A, Kesingland A, Gentry C, etal. The role of central and peripheral cannabinoid1 receptors in the antihyperalgesic activity of cannabinoids in a model of neuropathic pain. Pain. 2001;92:91-100.
14. Rog DJ, Nurmikko TJ, Friede T, Young CA. Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis. Neurology. 2005;65:812-819.
15. Rog DJ, Nurmikko TJ, Young CA. Oromucosal delta9-tetrahydrocannabinol/cannabidiol for neuropathic pain associated with multiple sclerosis: an uncontrolled, open-label, 2-year extension trial. Clin Ther. 2007;29:2068-2079.
16. Campbell FA, Tramer MR, Carroll D, etal. Are cannabinoids an effective and safe treatment option in the management of pain? A qualitative systematic review. BMJ. 2001;323:13-16.
17. Frank B, Serpell MG, Hughes J, etal. Comparison of analgesic effects and patient tolerability of nabilone and dihydrocodeine for chronic neuropathic pain: randomised, crossover, double blind study. BMJ. 2008;336:199-201.
18. Zajicek JP, Sanders HP, Wright DE, etal. Cannabinoids in multiple sclerosis (CAMS) study: safety and efficacy data for 12 months follow up. J Neurol Neurosurg Psychiatry. 2005;76:1664-1669.
19. Pinsger M, Schimetta W, Volc D, etal. Benefits of an adjuvant treatment with synthetic cannabinomimetic nabilone on patients with chronic pain: a randomized controlled trial. Wien Klin Wochenschr. 2006;118:327-335.
20. Wissel J, Haydn T, Muller J, etal. Low dose treatment with the synthetic cannabinoid nabilone significantly reduces spasticity-related pain: a double-blind placebo-controlled cross-over trial. J Neurol. 2006;253:1337-1341.
21. Abrams DI, Jay CA, Shade SB, etal. Cannabis in painful HIV-associated sensory neuropathy: a randomized placebo-controlled trial. Neurology. 2007;68:515-521.
22. Beaulieu P. Effects of nabilone, a synthetic cannabinoid, on postoperative pain. Can J Anaesth. 2006;53:769-775.
23. Berlach DM, Shir Y, Ware MA. Experience with the synthetic cannabinoid nabilone in chronic noncancer pain. Pain Med. 2006;7:25-29.
24. Skrabek RQ, Galimova L, Ethans K, Perry D. Nabilone for the treatment of pain in fibromyalgia. J Pain. 2008;9:164-173.
25. Ware MA, Fitzcharles M-A, Joseph L, etal. The effects of nabilone on sleep in fibromyalgia: results of a randomized controlled trial. Anesth Analg. 2010;110:604-610.
26. Rubin A, Lemberger L, Warrick P, etal. Physiologic disposition of nabilone, a cannabinol derivative, in man. Clin Pharmacol Ther. 1977;22:85-91.
27. Toth C, Au S. A prospective identification of neuropathic pain in specific chronic polyneuropathy syndromes and response to pharmacological therapy. Pain. 2008;138:657-666.
28. Bril V, Perkins BA. Validation of the Toronto Clinical Scoring System for diabetic polyneuropathy. Diabetes Care. 2002;25:2048-2052.
29. Perkins BA, Olaleye D, Zinman B, Bril V. Simple screening tests for peripheral neuropathy in the diabetes clinic. Diabetes Care. 2001;24:250-256.
30. Zelman DC, Gore M, Dukes E, etal. Validation of a modified version of the brief pain inventory for painful diabetic peripheral neuropathy. J Pain Symptom Manage. 2005;29:401-410.
31. Kind P, Dolan P, Gudex C, Williams A. Variations in population health status: results from a United Kingdom national questionnaire survey. BMJ. 1998;316:736-741.
32. Hays RD, Stewart AL. Sleep measures. In: Stewart AL, Ware JE, eds. Measuring Functioning and Well-Being: The Medical Outcomes Study Approach. Durham, NC: Duke University Press; 1992:235-259.
33. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983;67:361-370.
34. Meyer-Rosberg K, Burckhardt CS, Huizar K, etal. A comparison of the SF-36 and Nottingham Health Profile in patients with chronic neuropathic pain. Eur J Pain. 2001;5:391-403.
35. Notcutt W, Price M, Blossfeldt P, etal. Clinical experience of the synthetic cannabinoid nabilone for chronic pain. In: Nahas GG, Sutin KM, Harvey D, Agurell S, Pace N, Cancro R, eds. Marijuana and Medicine. Totowa, NJ: Humana Press, Inc.; 1999:567-572.
36. Gilron I, Bailey JM, Tu D, etal. Nortriptyline and gabapentin, alone and in combination for neuropathic pain: a double-blind, randomised controlled crossover trial. Lancet. 2009;374:1252-1261.
37. Serpell MG. Gabapentin in neuropathic pain syndromes: a randomised, double-blind, placebo-controlled trial. Pain. 2002;99:557-566.
38. Ware M, Wang T, Ducruet T, etal. Smoked cannabis for chronic neuropathic pain: results of a pilot study. In: 17th Annual Symposium on the Cannabinoids. Saint-Sauveur, Quebec, Canada: International Cannabinoid Research Society; 2007:31.
39. Karst M, Salim K, Burstein S, etal. Analgesic effect of the synthetic cannabinoid CT-3 on chronic neuropathic pain: a randomized controlled trial. JAMA. 2003;290:1757-1762.
40. Nurmikko TJ, Serpell MG, Hoggart B, etal. Sativex successfully treats neuropathic pain characterised by allodynia: a randomised, double-blind, placebo-controlled clinical trial. Pain. 2007;133:210-220.
41. Russo EB, Guy GW, Robson PJ. Cannabis, pain, and sleep: lessons from therapeutic clinical trials of Sativex, a cannabis-based medicine. Chem Biodivers. 2007;4:1729-1743.
42. Pollack MH, Matthews J, Scott EL. Gabapentin as a potential treatment for anxiety disorders. Am J Psychiatry. 1998;155:992-993.
43. Menigaux C, Adam F, Guignard B, etal. Preoperative gabapentin decreases anxiety and improves early functional recovery from knee surgery. Anesth Analg. 2005;100:1394-1399.
44. Attal N, Cruccu G, Haanpaa M, etal. EFNS guidelines on pharmacological treatment of neuropathic pain. Eur J Neurol. 2006;13:1153-1169.